EAN 2025 | The use of blood-based biomarkers to detect Alzheimer’s disease co-pathology in patients with PD
Angelo Antonini, MD, PhD, University of Padua, Padua, Italy, discusses the use of blood-based biomarkers to detect Alzheimer’s disease co-pathology in patients with Parkinson’s disease. Prof. Antonini emphasizes that this is crucial for identifying patients at risk of rapid deterioration. This interview took place at the 11th Congress of the European Academy of Neurology (EAN 2025) in Helsinki, Finland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
It’s a very important aspect we have been developing in recent years. We have understood that in many Parkinson’s patients there is not only one pathology. We have been convinced for many years that it’s all related to synuclein. But we found, thanks to these biomarkers that we can detect in the blood, that there is often co-pathology, co-Alzheimer pathology, at least there is amyloid deposition in the brain and we know that this co-pathology has an impact on disease progression...
It’s a very important aspect we have been developing in recent years. We have understood that in many Parkinson’s patients there is not only one pathology. We have been convinced for many years that it’s all related to synuclein. But we found, thanks to these biomarkers that we can detect in the blood, that there is often co-pathology, co-Alzheimer pathology, at least there is amyloid deposition in the brain and we know that this co-pathology has an impact on disease progression. Those Parkinson’s patients who deteriorate faster, they develop cognitive decline, they are most likely to have Alzheimer co-pathology. So the reason why people get two pathologies is still uncertain, but they all belong to the class of proteinopathy, so the protein degradation is affected. And probably starting with synuclein, other proteins get also involved. And if you do, I think this has an impact on progression and prognosis. Detecting this through a blood test, I think it’s very important, if you want to screen for those patients who are at risk of fast deterioration.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
